Brigitte Adams

Dr. Brigitte Adams


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 July 2017 in Acta Clinica Belgica
Verified
Journal Article
Closed access
KCKathleen Claes
Kathleen Claes
AMAnnick Massart
Annick Massart
LCLaure Collard
Laure Collard
LWLaurent Weekers
Laurent Weekers
EGEric Goffin
Eric Goffin
JWJohan Van de Walle
Johan Van de Walle
(2018). Belgian consensus statement on the diagnosis and management of patients with atypical hemolytic uremic syndrome. Acta Clinica Belgica: Vol. 73, No. 1, pp. 80-89.

4 October 2011 in Nephrology Dialysis Transplantation
Verified
Journal Article
Open access
PDF file
WTWilma F. Tromp
Wilma F. Tromp
NSNikki J. Schoenmaker
Nikki J. Schoenmaker
JLJohanna H. van der Lee
Johanna H. van der Lee
BABrigitte Adams
Brigitte Adams
ABAntonia H. M. Bouts
Antonia H. M. Bouts
JGJaap W. Groothoff
Jaap W. Groothoff
The low prevalence of childhood end-stage renal disease and the small centre sizes have been a barrier for clinical studies and the development of evidence-based guidelines for chronic renal replacement therapy (cRRT) in children. Few data exist on the quality of care for these patients and the applicability of existing guidelines. The aim of this study is to quantify variation in treatment policies and actually delivered care in nine centres that deliver cRRT for children. We surveyed treatment policies in all nine centres in the Netherlands and Belgium and compared them with the actually provided therapies and with recommendations from available guidelines. Data on treatment policies were gathered by questionnaires; actually provided care and outcomes were registered prospectively from 2007 to 2010. Data on policies and actual patient care were obtained from all nine centres. We found relevant differences between centres in treatment policies on various topics, e.g. estimated glomerular filtration rate threshold as an indication for initiation of cRRT, preferred initial mode of cRRT, peritoneal dialysis catheter care, haemodialysis frequency and vascular access. Discrepancies were seen between stated treatment policies and actual performed therapies. For the majority of policies, no evidence-based guidelines are available. Health care disparities exist due to large and unwanted variation in treatment policies between hospitals providing cRRT for children. Delivered care does not live up to stated policies, for which clear and internationally accepted guidelines are lacking.

16 March 2023 in Pediatric Nephrology
Verified
Journal Article
Closed access
PDF file
EBElke De Bruyne
Elke De Bruyne
LWLore Willem
Lore Willem
KHKoen Van Hoeck
Koen Van Hoeck
SRSarah Reynaert
Sarah Reynaert
SVSylvie Vankerckhove
Sylvie Vankerckhove
ELElena Levtchenko
Elena Levtchenko

7 November 2024 in American Journal of Transplantation
Verified
Journal Article
Open access
HKHenna Kaijansinkko
Henna Kaijansinkko
MBMarjolein Bonthuis
Marjolein Bonthuis
KJKirsi Jahnukainen
Kirsi Jahnukainen
JHJerome Harambat
Jerome Harambat
EVEnrico Vidal
Enrico Vidal
TJTimo Jahnukainen
Timo Jahnukainen
Cancer and its treatment may lead to kidney injury and need for kidney replacement therapy (KRT). We identified 287 pediatric KRT patients with a malignancy history from the ESPN/ERA Registry. Of these, 197 had cancer as a primary cause of KRT (group 1) and 90 had a malignancy diagnosis before KRT (group 2). Two matched controls without malignancy were randomly selected for each patient. Data were complemented with a questionnaire. Median time to kidney transplantation (KT) from KRT initiation was 2.4 (IQR: 1.5-4.7), 1.5 (IQR: 0.4-3.3), 3.6 (IQR: 1.3-Q3 not reached), and 1.1 (IQR: 0.3-3.6) years for group 1, their controls, group 2 and their controls, respectively. Overall 10-year mortality on KRT was higher among cancer patients vs. controls in group 1: 16% vs. 9% (aHR 2.02, 95% CI: 1.21-3.37) and in group 2: 23% vs. 14% (aHR 2.32, 95% CI: 1.11-4.85). In contrast, 10-year patient survival after first KT was comparable to controls (93% vs. 96%; 100% vs. 94%, in groups 1 and 2, respectively). In summary, childhood cancer survivors' KT was delayed, their overall mortality on KRT was increased, but once transplanted, their long-term outcome was similar to other KT recipients.

13 February 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
PGPauline Guillaume-Gentil
Pauline Guillaume-Gentil
BCBenedetta Chiodini
Benedetta Chiodini
BABrigitte Adams
Brigitte Adams
JHJean Herman
Jean Herman
MDMaria Van Dyck
Maria Van Dyck
KIKhalid Ismaïli
Khalid Ismaïli
Background/Objectives: To evaluate the outcome of developing BKPyV-DNAemia and presumptive BKPyV-nephropathy (BKPyV-DNAemia ≥ 104 copies/mL for more than 2 weeks) within the first 2 years post-transplant in a Belgian population of renal transplanted children. Methods: All children transplanted between 1 January 2010 and 31 December 2022 at Queen Fabiola Children’s University Hospital, Brussels (HUDERF) and at University Hospitals Leuven (UHL) were included in this retrospective study and 86 were followed for at least 2 years post-transplantation. Results: Within the first 2 years, 11/86 (13%) patients developed BKPyV-DNAemia ≥ 104 copies/mL (82% within the first 6 months). Among the 11 patients, 7 underwent a biopsy, of whom 4 were confirmed to have biopsy-proven BKPyV-nephropathy. Of those 11 patients, 4 (36%) developed an acute cellular rejection following immunosuppression reduction. The median eGFR at 2 years post-transplantation was 69 mL/min/1.73 m2 (IQR: 59–79) in the seven patients with presumptive BKPyV-nephropathy and 40 mL/min/1.73 m2 (IQR: 39–41) in the four with biopsy-proven BKPyV-nephropathy. At last follow-up visit, the median eGFR was 65 mL/min/1.73 m2 (IQR: 59–71) in the children with presumptive BKPyV-nephropathy, and 28 mL/min/1.73 m2 (IQR: 20–34) in the patients with biopsy-proven BKPyV-nephropathy. No risk factors for developing BKPyV-DNAemia were identified. Conclusions: Our study confirms that while BKPyV-DNAemia monitoring is essential in pediatric kidney transplant recipients, decisions based solely on viral load risk overtreatment and immunological complications. A personalized approach integrating viral, clinical, and immunological markers is urgently needed to balance infection control with graft preservation.